Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 91

1.

[First generation versus second generation antipsychotics: little benefit in the real world].

Schulte PF, Bogers JP, Steenhoek A.

Tijdschr Psychiatr. 2010;52(3):181-90. Dutch.

PMID:
20205081
[PubMed - indexed for MEDLINE]
Free Article
2.

[Prescribing patterns of antipsychotics in 13 French psychiatric hospitals].

Bret P, Bret MC, Queuille E.

Encephale. 2009 Apr;35(2):129-38. doi: 10.1016/j.encep.2008.03.007. Epub 2008 Jul 7. French.

PMID:
19393381
[PubMed - indexed for MEDLINE]
3.

Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).

Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, Murray RM, Markwick A, Lewis SW.

Arch Gen Psychiatry. 2006 Oct;63(10):1079-87.

PMID:
17015810
[PubMed - indexed for MEDLINE]
4.

'Real world' comparison of first- and second-generation antipsychotics in regard to length of inpatient hospitalization and number of re-hospitalizations.

Advokat C, Hill BD, Comaty JE.

Psychiatr Q. 2008 Mar;79(1):55-64. Epub 2007 Dec 1.

PMID:
18060498
[PubMed - indexed for MEDLINE]
5.

Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making.

Volavka J, Citrome L.

Expert Opin Pharmacother. 2009 Aug;10(12):1917-28. doi: 10.1517/14656560903061309. Review.

PMID:
19558339
[PubMed - indexed for MEDLINE]
6.

A meta-analysis of the efficacy of second-generation antipsychotics.

Davis JM, Chen N, Glick ID.

Arch Gen Psychiatry. 2003 Jun;60(6):553-64.

PMID:
12796218
[PubMed - indexed for MEDLINE]
7.

Evaluation of subjective treatment satisfaction with antipsychotics in schizophrenia patients.

Fujikawa M, Togo T, Yoshimi A, Fujita J, Nomoto M, Kamijo A, Amagai T, Uchikado H, Katsuse O, Hosojima H, Sakura Y, Furusho R, Suda A, Yamaguchi T, Hori T, Kamada A, Kondo T, Ito M, Odawara T, Hirayasu Y.

Prog Neuropsychopharmacol Biol Psychiatry. 2008 Apr 1;32(3):755-60. doi: 10.1016/j.pnpbp.2007.12.002. Epub 2007 Dec 14.

PMID:
18226436
[PubMed - indexed for MEDLINE]
8.

Using antipsychotic agents in older patients.

Alexopoulos GS, Streim J, Carpenter D, Docherty JP; Expert Consensus Panel for Using Antipsychotic Drugs in Older Patients.

J Clin Psychiatry. 2004;65 Suppl 2:5-99; discussion 100-102; quiz 103-4. Review.

PMID:
14994733
[PubMed - indexed for MEDLINE]
9.

Cost-benefit analysis of second-generation antipsychotics and placebo in a randomized trial of the treatment of psychosis and aggression in Alzheimer disease.

Rosenheck RA, Leslie DL, Sindelar JL, Miller EA, Tariot PN, Dagerman KS, Davis SM, Lebowitz BD, Rabins P, Hsiao JK, Lieberman JA, Schneider LS; Clinical Antipsychotic Trial of Intervention Effectiveness-Alzheimer's Disease (CATIE-AD) investigators.

Arch Gen Psychiatry. 2007 Nov;64(11):1259-68.

PMID:
17984395
[PubMed - indexed for MEDLINE]
10.

[Reaction on 'First generation versus second generation antipsychotics: little benefit in the real world'].

Lieverse R, Bet PM.

Tijdschr Psychiatr. 2010;52(5):357-8; author reply 358-60. Dutch. No abstract available.

PMID:
20458686
[PubMed - indexed for MEDLINE]
Free Article
11.

Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review.

Newcomer JW.

CNS Drugs. 2005;19 Suppl 1:1-93. Review.

PMID:
15998156
[PubMed - indexed for MEDLINE]
12.

[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].

Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.

Encephale. 2005 Mar-Apr;31(2):235-46. Review. French.

PMID:
15959450
[PubMed - indexed for MEDLINE]
13.

[Antipsychotics].

Cattapan-Ludewig K, Seifritz E.

Ther Umsch. 2009 Jun;66(6):402-6. doi: 10.1024/0040-5930.66.6.402. German.

PMID:
19496035
[PubMed - indexed for MEDLINE]
14.

The association between class of antipsychotic and rates of hospitalization: results of a retrospective analysis of data from the 2005 Medicare current beneficiary survey.

Kennedy J, Tien YY, Cohen LJ, Sclar DA, Liu D, Blodgett EG, Engle J.

Clin Ther. 2009 Dec;31(12):2931-9. doi: 10.1016/j.clinthera.2009.12.017.

PMID:
20110033
[PubMed - indexed for MEDLINE]
15.

Evaluating the cost-effectiveness of reduced tardive dyskinesia with second-generation antipsychotics.

Rosenheck RA.

Br J Psychiatry. 2007 Sep;191:238-45. Review.

PMID:
17766765
[PubMed - indexed for MEDLINE]
Free Article
16.

Determinants of first- and second-generation antipsychotic drug use in clinically unstable patients with schizophrenia treated in four European countries.

Barbui C, Nosè M, Mazzi MA, Bindman J, Leese M, Schene A, Becker T, Angermeyer MC, Koeter M, Gray R, Tansella M.

Int Clin Psychopharmacol. 2006 Mar;21(2):73-9.

PMID:
16421457
[PubMed - indexed for MEDLINE]
17.

Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia.

Rosenheck RA, Leslie DL, Sindelar J, Miller EA, Lin H, Stroup TS, McEvoy J, Davis SM, Keefe RS, Swartz M, Perkins DO, Hsiao JK, Lieberman J; CATIE Study Investigators.

Am J Psychiatry. 2006 Dec;163(12):2080-9.

PMID:
17151158
[PubMed - indexed for MEDLINE]
18.

A markov model of the cost effectiveness of olanzapine treatment for agitation and psychosis in Alzheimer's disease.

Kirbach S, Simpson K, Nietert PJ, Mintzer J.

Clin Drug Investig. 2008;28(5):291-303.

PMID:
18407715
[PubMed - indexed for MEDLINE]
19.

A randomized controlled trial of the cost-utility of second-generation antipsychotics in people with psychosis and eligible for clozapine.

Davies LM, Barnes TR, Jones PB, Lewis S, Gaughran F, Hayhurst K, Markwick A, Lloyd H; CUTLASS Team.

Value Health. 2008 Jul-Aug;11(4):549-62. doi: 10.1111/j.1524-4733.2007.00280.x. Epub 2007 Dec 18.

PMID:
18179662
[PubMed - indexed for MEDLINE]
20.

The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary.

Kane JM, Leucht S, Carpenter D, Docherty JP; Expert Consensus Panel for Optimizing Pharmacologic Treatment of Psychotic Disorders.

J Clin Psychiatry. 2003;64 Suppl 12:5-19.

PMID:
14640142
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk